Science Trust Fund Urged

WASHINGTON—A proposal to use the commercial fruits of federally funded research to finance new projects may get a hearing this fall in Congress. Although its passage is unlikely, the idea is seen as an innovative approach to funding R&D at a time when there is little room in the federal budget for new research programs. A bill (S. 1302) introduced May 29 by Sen. James Exon (D-Neb.) would create a technology trust fund with royalties from the sale of products that originated in federally

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—A proposal to use the commercial fruits of federally funded research to finance new projects may get a hearing this fall in Congress. Although its passage is unlikely, the idea is seen as an innovative approach to funding R&D at a time when there is little room in the federal budget for new research programs.

A bill (S. 1302) introduced May 29 by Sen. James Exon (D-Neb.) would create a technology trust fund with royalties from the sale of products that originated in federally funded research. It would require institutions and individuals receiving federal grants and contracts to give to the trust a small portion of any profits derived from the research.

In introducing the bill, Exon suggested that the government receive royalties of 2 to 5 percent from sales of a product or process. “This minimal percentage will not discourage research efforts,” he said.

A broader proposal for a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies